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1100Progression of Retinal Pigment Epithelial
Atrophy in Antiangiogenic Therapy
of Neovascular Age-Related Macular
DegenerationCHRISTOPHER SCHU¨TZE, MANUELA WEDL, BERNHARD BAUMANN, MICHAEL PIRCHER,
CHRISTOPH K. HITZENBERGER, AND URSULA SCHMIDT-ERFURTH PURPOSE: To monitor retinal pigment epithelial (RPE)
atrophy progression during antiangiogenic therapy of
neovascular age-related macular degeneration (AMD)
over 2 years using polarization-sensitive optical coher-
ence tomography (OCT).
 DESIGN: Prospective interventional case series.
 METHODS: SETTING: Clinical practice. STUDY POPULA-
TION: Thirty patients (31 eyes) with treatment-naı¨ve
neovascular AMD. OBSERVATION PROCEDURES: Standard
intravitreal therapy (0.5 mg ranibizumab) was adminis-
tered monthly during the first year and pro re nata
(PRN; as-needed) during the second year. Spectral-
domain (SD) OCT and polarization-sensitive OCT
(selectively imaging the RPE) examinations were
performed at baseline and at 1, 3, 6, 12, and 24 months
using a standardized protocol. RPE-related changes
were evaluated using a semi-automated polarization-
sensitive OCT segmentation algorithm and correlated
with SD OCT and fundus autofluorescence (FAF) find-
ings. MAIN OUTCOME MEASURES: RPE response, geographic
atrophy (GA) progression.
 RESULTS: Atrophic RPE changes included RPE thin-
ning, RPE porosity, focal RPE atrophy, and development
of GA. Early RPE loss (ie, RPE porosity, focal atrophy)
increased progressively during initial monthly treatment
and remained stable during subsequent PRN-based ther-
apy. GA developed in 61% of eyes at month 24. Mean
GA area increased from 0.77 mm2 at 12 months to
1.10 mm2 (standard deviation [ 1.09 mm2) at
24 months. Reactive accumulation of RPE-related mate-
rial at the lesion borders increased until month 3 and sub-
sequently decreased.
 CONCLUSIONS: Progressive RPE atrophy and GA
developed in the majority of eyes. RPE migration signifies
certain RPE plasticity. Polarization-sensitive OCT specif-
ically images RPE-related changes in neovascular AMD,r publication Feb 16, 2015.
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A
GE-RELATED MACULAR DEGENERATION (AMD) IS A
progressive disease leading to substantial visual
loss.1–3 Independent of the 2 classic pathways of
disease progression with an atrophic or a neovascular
development, a leading pathophysiologic role of the
retinal pigment epithelium (RPE) has been recognized.4,5
Defects in the RPE layer continuity with abnormal
choroidal vessel growth cause leakage and fluid
accumulation resulting in rapid deterioration of vision5
owing to successive damage to the overlying retina, while
clinically masking RPE morphology.
Vascular endothelial growth factor (VEGF)-A is a key
factor in the pathogenesis of choroidal neovascularization
(CNV).6–8 Milestone clinical trials have demonstrated
significant efficacy in terms of improving visual acuity
(VA) with monthly injections of ranibizumab. The
antibody fragment inhibits binding of multiple active
forms of VEGF-A to their receptors, resolves leakage, and
restores retinal morphology and often function, and became
the first-line treatment for neovascular AMD.9–14 Recently,
an increased progression rate of geographic atrophy (GA)
has been recognized during anti-VEGF therapy.15,16
Together with anti-VEGF therapy, high-resolution im-
aging technologies such as spectral-domain optical coher-
ence tomography (SD OCT) that obtain high-resolution
retinal images have become increasingly important modal-
ities in the diagnosis and therapeutic management of
neovascular AMD.17 However, current SD OCT technol-
ogy visualizes retinal structures exclusively by intensity-
based imaging and has substantial limitations in identifying
the RPE owing to difficulties in segmenting structures of
similar reflectivity. A distinct evaluation of RPE
morphology would be of major relevance to gain insight
into the primary pathophysiology of AMD, the biologic
response to anti-VEGF therapy, and long-term prognosis.0002-9394/$36.00
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FIGURE 1. Polarization-sensitive optical coherence tomography imaging allows for selective differentiation of the retinal pigment
epithelium based on intrinsic tissue-specific polarization contrast. An overlay of an intensity image and the segmented retinal pigment
epithelium (RPE; red) in a healthy subject is shown (Top left). The degree of polarization uniformity (DOPU) image selectively de-
lineates the RPEmorphology (Top right). Central retinal thickness (CRT) maps may be generated (Bottom left), as well as a selective
RPE thickness map (Bottom right).Recently, polarization-sensitive OCT has been intro-
duced,18–20 providing morphologic information beyond
nonspecific back-scattered intensity patterns, selectively
identifying the RPE by measuring several intrinsic tissue
qualities simultaneously with spectral-domain high-
resolution imaging (reflectivity, retardation, optic axis
orientation, degree of polarization uniformity
[DOPU]).18–20 Polarization-sensitive OCT provides
distinct identification of the RPE condition in AMD with
drusen,21,22 advanced dry AMD,22,23 and neovascular
AMD.24 The purpose of the current study was to identify
characteristic RPE changes in patients with neovascular
AMD undergoing continuous anti-VEGF therapy from
early to advanced changes using polarization-sensitive
OCT together with conventional SD OCT.METHODS
 INCLUSION AND EXCLUSION CRITERIA: Thirty treat-
ment-naı¨ve patients (31 eyes) with neovascular AMD
were included in this prospective interventional case series.
The mean age of patients was 82 (standard deviation [SD]:
8) years; 18 patients were female and 12 were male. The
character and possible consequences of the study were
explained in detail prior to inclusion. Each patient gave
signed informed consent. Ethics Committee approval
(Medical University of Vienna) was obtained. The studyVOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICadhered to the tenets of the Declaration of Helsinki and
to all federal laws of Austria. This study is registered at
https://eudract.ema.europa.eu/, number 2006-005684-26.
Active subfoveal CNVwas identified using protocol fluo-
rescein angiography (FA) and conventional SD OCT
(Spectralis OCT;Heidelberg Engineering,Heidelberg, Ger-
many) that showed retinal thickening>250 mm. Exclusion
criteria were other retinal diseases including primary GA,
retinal dystrophies, and severe media opacities. All patients
underwent a standardized ophthalmologic examination
including best-corrected visual acuity (BCVA) using Early
Treatment Diabetic Retinopathy Study (ETDRS) letters,
slit-lamp biomicroscopy, fundus photography, and FA.
 RETINALPIGMENTEPITHELIUMIMAGING: Patients were
imaged by conventional SDOCT, by fundus autofluorescence
(FAF), and by a polarization-sensitive OCT prototype specif-
ically imaging the RPE, developed by the Center for Medical
Physics and Biomedical Engineering, Medical University of
Vienna, used previously.21–24 Retinal and RPE morphology
was assessed prior to anti-VEGF treatment (baseline) and at
1, 3, 6, 12, and 24 months following baseline.
Polarization-sensitive OCT measures reflectivity, retar-
dation, optic axis orientation, and DOPU18 simultaneously
and images retinal morphology, the RPE, and related depo-
larizing structures containing melanin. Details of the
instrument have been published.22 RPE identification is
based on its depolarizing quality, scrambling the polarization
state of back-scattered light, while light back-scattered from1101THERAPY IN NEOVASCULAR AMD
FIGURE 2. Characteristic changes of the retinal pigment epithelium detected by polarization-sensitive optical coherence tomography
in antiangiogenic therapy of neovascular age-related macular degeneration. (Top row) Retinal pigment epithelial (RPE) porosity
(dashed brace). (Second row) Focal RPE atrophy (circle). (Third row) RPE thinning (dotted brace). (Fourth row) Thickening of
the RPE layer (rectangle). (Bottom row) Ectopic depolarizing material in outer retinal layers (arrow).other retinal layers remains in a well-defined polarization
state. High-resolution 3D polarization-sensitive OCT data-
sets are recorded in 3.3 seconds with a raster scanning speed
of 20 000 A-scans/s and 4.5 mm axial resolution. A 6.2 3
6.7 mm2 scanning area and a 128 B-scans 3 512 A-scans
scanning density was used, enabling best image quality.
RPE segmentationwas performed by an algorithm based on
Stokes vector analysis.18 Stokes vector elements were aver-
aged over adjacent pixels by calculating the mean value of
each Stokes vector element within a rectangular evaluation
window. The DOPU value related to the degree of polariza-1102 AMERICAN JOURNAL OFtion was then calculated as a function of position. In
polarization-preserving or birefringent tissue, DOPU is
approximately 1; in the case of a depolarizing layer, DOPU
is lower than 1. Red, orange, or yellow colors inDOPU images
indicate polarization-preserving tissue (ie, retinal layers other
than theRPE). TheRPE appears as a depolarizing layer (green
to blue colors) providing selective differentiation. By thresh-
olding the DOPU image, areas of DOPU<0.8 were regarded
as depolarizing RPE and used to generate an overlay of the
segmented RPE and the intensity SD OCT image enabling
visualizationof retinal layers togetherwith theRPE (Figure 1).JUNE 2015OPHTHALMOLOGY
FIGURE 3. Best-corrected visual acuity and central retinal thickenss values during follow-up in antiangiogenic therapy of neovas-
cular age-related macular degeneration. Compared to month 0 (baseline), statistical significance was P[ .98 at month 24 for best-
corrected visual acuity (BCVA) and P< .01 for central retinal thickness (CRT). Bars and stars indicate standard deviation. INTENSITY-BASED SPECTRAL-DOMAIN OPTICAL
COHERENCE TOMOGRAPHY IMAGING: Spectralis SD
OCT high-resolution macular raster scans, scans of the
foveal region, and macular thickness maps were used in
this study. Intensity-based SDOCT B-scans were compared
to polarization-sensitive OCT images regarding RPE integ-
rity and correlations of hyperreflective material with depo-
larizing foci in outer retinal layers. Scanning angle was 20
degrees, scan diameter measured 6000 mm, and 20 high-
resolution frames were averaged per B-scan.
 SEMIAUTOMATED SEGMENTATION OF RETINAL
PIGMENT EPITHELIUM ATROPHY BY POLARIZATION-
SENSITIVE OPTICAL COHERENCE TOMOGRAPHY: An
automated segmentation algorithm22 was developed for
GA lesion quantification in dry AMD and used in a semi-
automated fashion for measuring lesions in neovascular
AMD in this study. The height of the evaluation band
used to sum up the number of depolarizing pixels along
each A-line was adjusted manually depending on the cur-
vature of the pathologic RPE (ie, in case of pigment epithe-
lial detachment) and on the amount of choroidal
depolarizing pixels. Using the evaluation band, the algo-
rithm excluded depolarizing signals below the RPE/Bruch
membrane complex and is therefore described as semiauto-
mated. The algorithm analyzes depolarizing pixels along
eachA-line of a segmented 3D dataset, subsequently gener-
ating a thickness map of depolarizing tissue that was then
binarized and smoothed to precisely assess GA dimensions.
The algorithm automatically detects patches of connected
pixels, marks them as atrophic, and calculates the corre-
sponding atrophy area by scaling with the known pixel
area.
 TREATMENT PROCEDURES: Patients received monthly
injections of ranibizumab (Lucentis; Novartis Pharma
AG, Basel, Switzerland, and Genentech Inc, South SanVOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICFrancisco, California, USA) during the first 12 months
and were treated pro re nata (PRN; as needed) frommonths
12–24 following the Comparison of Age-related Macular
Degeneration Treatments Trials (CATT) protocol.10 Sum-
marized, patients were scheduled for monthly monitoring
visits according to protocol and underwent a complete ex-
amination including standardized BCVA testing and SD/
polarization-sensitive OCT imaging.
Retreatments were performed if visual deterioration
occurred or active CNV was evident. Most retreatment de-
cisions were made according to presence or absence of fluid
in OCT. Eyes were retreated except if fluid did not decrease
following 3 consecutive monthly injections. Treatment was
reinstituted at later visits if increased fluid was detected on
OCT. If other signs of active CNV presented (including
persistent intraretinal or subretinal hemorrhage, new subre-
tinal hemorrhage, decreased VA relative to last visit without
other explanation, leakage on FA, or increased lesion size on
FA relative to last angiogram) patients were treated.
A total of 0.5 mg ranibizumab was injected intravitreally
using a 30 gauge needle.
 MORPHOLOGIC PARAMETERS AND DATA ANALYSES:
Two independent graders analyzed polarization-sensitive and
SD OCT images in a masked and random fashion regarding
patient, treatment assignment, and visit. Based on
polarization-sensitiveOCT,RPE-specific changeswere graded
qualitatively as: RPE thinning, RPE porosity, focal RPE atro-
phy, GA areas, and regulatory RPEmigration including accu-
mulations of depolarizing material at the RPE level or ectopic
depolarizing material within outer retinal layers.
RPE porosity was classified as series of RPE layer gaps over
a width of at least 20% of a polarization-sensitive OCT
B-scan, with several depolarizing RPE residuals between
atrophic regions (Figure 2, dashed brace). Focal RPE atro-
phy was defined as isolated atrophic regions in the RPE,1103THERAPY IN NEOVASCULAR AMD
FIGURE 4. Comparison of polarization-sensitive optical coher-
ence tomography and spectral-domain optical coherence tomog-
raphy findings in antiangiogenic therapy of neovascular
age-related macular degeneration. The position of the respective
B-scans is marked (Top); the intensity-based spectral-domain
(SD) optical coherence tomography (OCT) image is shown
(Middle) and is correlated with the intensity/retinal pigment
epithelium (RPE) overlay (Bottom) generated by polarization-
sensitive OCT. Severe RPE irregularities were unambiguously
detectable by polarization-sensitive OCT in contrast to
intensity-based SD OCT, where the condition of the RPE was
not identifiable (rectangles). Although an increased light pene-
tration into the choroid is seen in the intensity-based SD OCT
image (Middle), associated atrophic RPE and thinned RPE are
only unambiguously identifiable using polarization-sensitive
OCT (Bottom).
1104 AMERICAN JOURNAL OFnot quantifiable as advanced GA by the segmentation algo-
rithm (Figure 2, circle). RPE thinning was defined as an
RPE segmentation band thinner than half the normal
RPE segmentation band thickness over a width of at least
10% of a B-scan (Figure 2, dotted brace). GA was defined
as atrophic RPE lesions >_0.1 mm2 (minimal GA area
detectable by the algorithm).
Accumulation of depolarizing material at the RPE level
was defined as an RPE area at least twice as thick as normal
RPE identified in a B-scan outside of the AMD lesion
(Figure 2, rectangle). Ectopic depolarizing material was
specified as depolarizing structures in outer retinal layers,
discontinuous from the RPE (Figure 2, arrow).
Quantitative evaluation of presence or absence of
described features during follow-up was performed: all
polarization-sensitive OCT B-scans were evaluated at
each visit and a score of 0 or 1 was assigned for absence
(0) or presence (1) of a specific RPE lesion type. The propor-
tion of eyes with evidence of each lesion type was expressed
as a percentage for each visit.
Fellow eyes were analyzed and compared to eyes with
CNV treated with anti-VEGF based on polarization-
sensitive OCT and conventional intensity-based SD
OCT. Fellow eyes that developed CNV were immediately
treated as needed using intravitreal ranibizumab.
Interobserver variability of qualitative polarization-
sensitive OCT results was tested using k statistics and by
calculating percentage of agreement. Spearman correlation
coefficients were used to evaluate agreement of identified
lesion analyses between observers.
BCVA and central retinal thickness (CRT) (using
Spectralis-OCT) were compared during follow-up. The
paired sample t test was used for BCVA and CRT assessment
and for comparison ofGAarea between different time points.
Software used was MedCalc version 14.12.0 (Informer Tech-
nologies, Inc.), Excel 2007 (Microsoft), andPhotoshopCS5.1
(Adobe). P < .05 was considered statistically significant.RESULTS
 CHANGES IN CLINICAL PARAMETERS: At enrollment,
BCVA ranged from 20/40 to 20/320. Mean BCVA was
57.7 (range: 14–90) ETDRS letters at baseline and 56.3
(SD: 19.4) letters at month 24 (P ¼ .98). Mean CRT was
450.9 mm (SD: 128.6) at baseline and 323.9 mm (SD:
124.8) at month 24 (P < .01). Figure 3 summarizes the re-
sults. Mean number of anti-VEGF treatments was 9.9
(range: 3–12) between months 0 and 12 and 3.2 (range:
0–6) between months 12 and 24.
 QUALITATIVE IDENTIFICATION OF RETINAL PIGMENT
EPITHELIAL MORPHOLOGY BY OPTICAL COHERENCE
TOMOGRAPHY IMAGING: Primary RPE-related alterations
caused by the neovascular pathology and/or secondarilyJUNE 2015OPHTHALMOLOGY
FIGURE 5. Development of retinal pigment epithelial atrophy under anti–vascular endothelial growth factor treatment in neovas-
cular age-related macular degeneration as detected by polarization-sensitive optical coherence tomography. (Percentages of affected
eyes are plotted over time.) Pathognomonic signs of early retinal pigment epithelial (RPE) loss including porosity and focal atrophy
increased substantially during the first year of monthly intravitreal treatment and remained stable during the second year with an as-
needed retreatment strategy. Areas of geographic atrophy developed over 2 years in 61% of eyes.
FIGURE 6. Example of retinal pigment epithelial loss associated with retinal features in antiangiogenic therapy of neovascular age-
related macular degeneration. Significant atrophy of the retinal pigment epithelium (RPE) was frequently apparent beneath regions of
subretinal fluid (Top; dotted rectangle) or intraretinal cysts (Top; dashed rectangle), specifically detectable by polarization-sensitive
optical coherence tomography. (Top) Intensity/RPE overlay; (Bottom) Degree of polarization uniformity. Note that there is suffi-
cient signal penetration present through all retinal layers, allowing for the precise identification of RPE atrophy.associated with anti-VEGF therapy (RPE atrophy and RPE
migration) were consistently identifiable by polarization-
sensitive OCT (Figure 2). While conventional intensity-
based SD OCT demonstrated a continuous RPE layerVOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICfeature in the majority of cases, polarization-sensitive
OCT revealed distinct RPE discontinuities as well as RPE
thinning/thickening within the lesion area (Figure 4). At
baseline RPE porosity was identified in 23% and focal1105THERAPY IN NEOVASCULAR AMD
FIGURE 7. Box-plot analysis of progression in geographic atrophy lesion size during antiangiogenic therapy of neovascular age-
related macular degeneration. Although no geographic atrophy (GA) was detectable before treatment, the GA lesion size increased
steadily over time. P values refer to changes in relation to previous visit. Gray dots refer to outliers. Mean values of GA area are given
for each visit.atrophy in 55% of eyes (Figure 5). RPE atrophy was mostly
associated with fluid or intraretinal cysts in SD OCT
(Figure 6).
 PROGRESSIONOFRETINAL PIGMENTEPITHELIALATRO-
PHY IN POLARIZATION-SENSITIVE OPTICAL COHERENCE
TOMOGRAPHY: Continuous progression of RPE loss could
be measured during follow-up, based on polarization-
sensitive OCT images at each designated visit.
RPE porosity, detected in 7 of 31 eyes (23%) at baseline,
increased to 20 affected eyes (65%) at months 12 and 24
during anti-VEGF therapy. Focal RPE atrophy was
observed in 17 eyes (55%) at baseline, while following 12
and 24 months 30 eyes (97%) were affected and only 1
eye did not show any area of RPE discontinuity.
No GA lesion was detected by the semiautomated seg-
mentation algorithm in any of the 31 eyes at baseline.
However, following 12 months of monthly treatment
with anti-VEGF, GA was detected in 17 eyes (55%), and
in 19 eyes (61%) at month 24. Of all patients in whom
GA was detected, mean GA dimensions were 0.77 mm2
(SD: 0.67, range: 0.12–2.58 mm2) at month 12 and
1.10 mm2 (SD: 1.09, range: 0.14–2.58 mm2) at month 24
(Figure 7), showing continuous expansion throughout a
fixed and a flexible regimen. Eyes with CNV that devel-
oped GA showed subretinal drusenoid deposits (SDD) in
5 eyes (26%) at month 24. Twenty-six percent of eyes
with CNV developing GA showed SDD prior to the visit
when GA was first detected. All eyes with SDD and GA
revealed multilobular GA.
Figure 8 shows a representative example of GA detection
by polarization-sensitive OCT in a patient treated with
anti-VEGF clearly highlighting progressive GA enlarge-1106 AMERICAN JOURNAL OFment. Comparing polarization-sensitive OCT with
intensity-based SD OCT and FAF imaging, only
polarization-sensitive OCT precisely identifies atrophic
RPE. Following 24 months of treatment, 9 of 31 eyes
(29%) revealed foveal GA, 5 eyes (16%) extrafoveal GA,
and 5 eyes (16%) both foveal and extrafoveal GA.
One patient (1 eye, 3%) was affected by RPE thinning at
baseline, 4 eyes (13%) at month 12, and 3 eyes (10%) at
month 24 following anti-VEGF therapy.
 EVALUATION OF RETINAL PIGMENT EPITHELIUM
MIGRATION DETECTED BY POLARIZATION-SENSITIVE
OPTICAL COHERENCE TOMOGRAPHY: In addition to
atrophic changes, an increase in RPE-related material
was noted simultaneously and interpreted as reactive RPE
migration/hyperplasia, initially increasing until month 3,
followed by a decrease of RPE response throughout month
24 (Figure 9).
Accumulations of RPE-derived depolarization presented
in 7 of 31 eyes (23%) prior to treatment, reaching a
maximum at month 3 following anti-VEGF therapy (19
eyes, 61%). Eleven eyes (36%) revealed this pattern at
month 12 and 8 eyes (26%) at month 24. A typical ring-
shaped appearance of accumulating depolarizing material
encapsulating the CNV lesion was observed in 3 eyes
with classic CNV (Figure 10). All ring-shaped RPE accu-
mulations progressed toward RPE atrophy with treatment
continuation.
Ectopic depolarizing material in outer retinal layers
changed from 26 affected eyes (26/31, 84%) at baseline to
19 eyes (19/31, 61%) at month 12 and 16 eyes (16/31,
52%) at month 24. These accumulations were located
within the outer nuclear layer (ONL) and consistentlyJUNE 2015OPHTHALMOLOGY
FIGURE 8. Example of geographic atrophy (GA) progression detected by the semiautomated polarization-sensitive optical coherence
tomography (OCT) segmentation algorithm in antiangiogenic therapy of neovascular age-related macular degeneration. Prior to the
first injection (baseline) isolated focal retinal pigment epithelial (RPE) atrophy is present (Top left: arrows), progressing in size at
month 6 (dotted rectangle in the polarization-sensitive OCT B-scan, Top left). The semiautomated polarization-sensitive OCT seg-
mentation algorithm first detected a distinct GA lesion at month 12 (Top middle: thickness map of depolarizing material, lesion size:
1.08 mm2; the dashed rectangle indicates corresponding RPE atrophy in the polarization-sensitive OCT B-scan), progressing to
2.30 mm2 at month 24 (Top right: dashed rectangle indicates corresponding RPE atrophy in the polarization-sensitive OCT B-
scan). Identical B-scan locations are shown for all time points presented. Intensity/RPE overlay (Top left, Top middle, Top right);
degree of polarization uniformity (Top left, Top middle, Top right); pseudo–scanning laser ophthalmoscopy image with marked B-
scan position (Top left, Top middle, Top right); RPE thickness map (Top middle, Top right); map indicating increasing GA dimen-
sions over time (Top middle, Top right). The 2 boxes below (Bottom left, Bottom right) represent the identical patient at 12 and
24 months following anti–vascular endothelial growth factor therapy. Note that the status of the RPE is only unambiguously identifi-
able in the polarization-sensitive OCT B-scans compared to conventional intensity-based spectral-domain OCT imaging. In the
fundus autofluorescence images (Bottom left, Bottom right) it is not possible to identify regions of GA and borders of the atrophic
zone, whereas the polarization-sensitive OCT maps (Top middle, Top right) specifically identify GA.corresponded to intraretinal foci in intensity-based SD
OCT (Figure 11).
 MORPHOLOGIC ANALYSIS OF FELLOW EYES: Fifteen
fellow eyes (48%) developed neovascular AMD until
month 24 of follow-up, revealing RPE-related changes
as described above, and were therefore excluded from anal-
ysis.
Five fellow eyes (31%) showed GA related to dry AMD
at baseline, 1 eye (6%) developed GA at month 6. All GA
lesions increased progressively until month 24. Drusen
presented at a variable extent in all eyes, increasing in
number and area in 5 eyes (31%) until month 24. Three
fellow eyes (19%) showed drusen regression resulting inVOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICfocal RPE atrophy or GA until month 24. SDD presented
in 13 eyes (81%) at month 24.
In addition to fellow eyes with GA related to dry AMD,
3 eyes (19%) showed focal RPE atrophy, noted at baseline
in 2 eyes (13%). These eyes showed isolated focal RPE at-
rophy on top of a druse, of which 1 eye (6%) remained
stable and the other eye showed RPE atrophy progression
through month 24. One eye first revealed focal RPE atro-
phy at month 12 and showed consecutive RPE atrophy pro-
gression until month 24. RPE porosity or RPE thinning was
not detected in fellow eyes without GA related to dry
AMD.
Excluding fellow eyes with CNV, accumulations of depo-
larizing material in outer retinal layers appeared in 11 eyes1107THERAPY IN NEOVASCULAR AMD
FIGURE 9. Development of reactive hyperplasia/migration of the retinal pigment epithelium over time detected by polarization-
sensitive optical coherence tomography in antiangiogenic therapy of neovascular age-related macular degeneration. The proportion
of eyes showing accumulation of retinal pigment epithelium (RPE)-related material at the lesion borders increases until month 3
and subsequently decreases continuously until month 24. RPE-related depolarizing material within outer retinal layers steadily de-
creases following treatment initiation.(69%) and remained stable in 8 eyes (50%) until month 24.
Accumulations of depolarizing material in outer retinal
layers increased in 1 of these eyes from months 12–24; 2
eyes showed a decrease from baseline through month 24.
 REPRODUCIBILITY OF READING PROCEDURES: The
Table summarizes interobserver reproducibility of qualita-
tive grading of RPE lesion types in polarization-sensitive
OCT B-scans. Highest reproducibility (k ¼ 1.0) was found
for semiautomated GA detection and lowest for RPE thin-
ning (k ¼ 0.39). Overall agreement was 88%. Semiauto-
mated GA segmentation agreement between observers
was consistently high, with r ¼ 0.9 (Spearman correlation
coefficient).DISCUSSION
THIS STUDY QUALITATIVELY AND QUANTITATIVELY IDEN-
tifies the morphologic response of the RPE during anti-
VEGF therapy for neovascular AMD. SD and
polarization-sensitive OCT (specifically detecting the
RPE) were used to continuously monitor RPE changes
before and during anti-VEGF treatment over a follow-up
period of 24 months. Characteristic changes of RPE1108 AMERICAN JOURNAL OFmorphology were described, including RPE loss and RPE
accumulation.
In this study, an increasing number of eyes showing early
RPE atrophy such as RPE porosity occurred with treatment
initiation and increased over time, reaching a peak of 65%
affected eyes at month 24. Focal RPE atrophy increased
with an identical pattern. Compared to GA in dry AMD,
presenting with larger RPE atrophy lesions,25–27 RPE
atrophy in neovascular AMD and associated treatment
showed multiple smaller and more diffusely distributed focal
atrophic RPE lesions. The multilobular GA structure
frequently observed in eyes with CNV of the present study
may represent an underlying disease substrate, for example,
the choroidal vasculature, recently reported by Xu and
associates.28 Patients with CNV undergoing therapy
frequently developed these discrete RPE discontinuities
increasing in size and distribution during follow-up. Jaffe
and associates29 showed that RPE atrophy other than GA
(ie, depigmented RPE without clearly defined boundaries)
developed in 15%of eyes under the foveal center in the Com-
parison of Age-related Macular Degeneration Treatments
Trials based on fundus photography and FA. The higher num-
ber of patients affected by focal RPE atrophy in our study
could be caused by a superior RPE specificity of
polarization-sensitive OCT and the fact that these focal
RPE lesions were diffusely distributed and not exclusively
located subfoveally. Interestingly, localized RPE atrophy wasJUNE 2015OPHTHALMOLOGY
FIGURE 10. Accumulations of depolarizing retinal pigment epithelium structures detected by polarization-sensitive optical coher-
ence tomography at baseline (Top) and 6 months (Middle, Bottom) following antiangiogenic therapy initiation of neovascular
age-related macular degeneration. In its most advanced form, accumulating retinal pigment epithelium (RPE) at the lesion margins
demonstrates a ring-shaped appearance surrounding a classic neovascular lesion. Intensity/RPE overlay (Top left, Middle left); degree
of polarization uniformity image (Top right, Middle right); pseudo–scanning laser ophthalmoscopy image (Bottom left); thickness
map of depolarizing material (Bottom right); note the increased presence of accumulations of depolarizing material at the RPE level
at 6 months compared to baseline (rectangles).frequently observed beneath intraretinal cysts and fluid accu-
mulation, associated with dysfunctional neurosensory retina.
Recent studies indicated that patients with CNV devel-
oped GA16,29 following anti-VEGF therapy. Grunwald and
associates16 reported that 18.3% of patients developed GA
within 2 years of anti-VEGF therapy using color fundus
photography and FA only. Our study even reveals a linear
increase in atrophic RPE features and GA dimensions using
polarization-sensitive OCT (61% of GA at month 24). Us-
ing the polarization-sensitive OCT-related algorithm, GA
was defined as an area >_0.1 mm2 in our study—superior to
FA/scanning laser ophthalmoscopy–based detection of
GA, commonly defined as an atrophic RPE lesion
measuring at least 250 mm in longest linear diameter.16
In the current study identification of GA in eyes with
CNV was particularly difficult using FAF imaging, whereasVOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICpolarization-sensitive OCT accurately delineated atrophic
RPE (Figure 8). Noteworthy, early atrophic RPE changes
(porosity, focal lesions) and expansion of advanced GA
was most pronounced during intensive monthly retreat-
ment, consistent with findings in the CATT study and a
higher rate of GA in the monthly treatment arm.
Schmitz-Valckenberg and associates30 recently showed
an association of SDD with GA in dry AMD in 62% of
eyes. Our study revealed SDD in only 26% of eyes with
GA related to neovascular AMD treated with anti-
VEGF at month 24 of follow-up. This supports the hy-
pothesis of an association between GA formation and
anti-VEGF therapy that is not linked to progressive dry
AMD.
Our findings of progressive RPE atrophy in CNV may
therefore indicate a potential complication of VEGF1109THERAPY IN NEOVASCULAR AMD
FIGURE 11. Accumulations of depolarizing material in outer
retinal layers in antiangiogenic therapy of neovascular age-
related macular degeneration detected by polarization-sensitive
optical coherence tomography corresponded to intraretinal
hyperreflective accumulations in intensity-based spectral-
domain (SD) optical coherence tomography (OCT). The
polarization-sensitive OCT degree of polarization uniformity
(Top) and intensity/retinal pigment epithelium overlay images
(Middle), signifying intraretinal depolarizing material, are illus-
trated (circle). The intensity-based SD OCT scan (Bottom) re-
veals corresponding intraretinal hyperreflective material.inhibition at the RPE level, in addition to the natural dis-
ease course of neovascular AMD primarily causing RPE
damage. Although it is not possible to distinguish between
the natural disease course and anti-VEGF therapy being the
reason for RPE atrophy development, the linear progression
over time, the association between intensity of the thera-
peutic regimen, and the concomitant extent of RPE loss
nevertheless support this hypothesis. However, the contin-
uous increase of RPE atrophy detected by polarization-
sensitive OCT emphasizes the need for a tight assessment
of treatment indication for anti-VEGF therapy in neovascu-
lar AMD (avoiding unnecessary therapeutic interventions)
to balance benefit and risk. Obviously, although results of
our study and other investigations indicate that anti-
VEGF therapy may accelerate RPE atrophy in neovascular1110 AMERICAN JOURNAL OFAMD, treatment is indispensable, otherwise risking pro-
gression of disease to legal blindness.
Regarding the reactive response of the RPE to the ther-
apeutic effect (ie, hyperplasia/migration), different pat-
terns were detected by polarization-sensitive OCT in this
study, signifying RPE plasticity to some extent. These pat-
terns were generally decreasing until month 24 of follow-
up, ending in atrophy. Accumulations of depolarizing
structures at the RPE level were most pronounced at month
3, declining toward month 24, which may be consistent
with an increase in metabolic activity, dynamic migrating
processes, or cellular proliferation, in particular during res-
olution of exudation in the first 3 months of anti-VEGF
therapy. An increase of depolarizing material at the borders
of the RPE lesion revealed a topographic correlation to hy-
perpigmentation in biomicroscopy, supporting the concept
of RPE hyperplasia/migration.
Ring-shaped accumulations of depolarizing material at
the RPE level surrounding the CNV lesion could indicate
an encapsulating, migrating, or extensively proliferating
activity of RPE cells at the borders of a regressing CNV
lesion, possibly induced by anti-VEGF, described earlier.31
A ring-shaped appearance has also been noted in infrared
imaging by Semoun and associates,32 correlating to the
boundaries of the CNV lesion. Our findings of RPE accu-
mulation in polarization-sensitive OCT are further
supported by previous in vitro histologic studies, showing
RPE recovery accomplished by RPE proliferation and hy-
perplasia,33 signifying RPE recovery in AMD.34 Therefore,
it may be suggested that the benefit of anti-VEGF therapy
could also originate from RPE recovery in cases where RPE
migration or proliferation is observable in polarization-
sensitive OCT, and not solely from resolution of retinal
edema.
The origin of accumulations of depolarizing material in
outer retinal layers is unclear, possibly representing exuda-
tive components such as previously described lipid
exudates35 containing melanin from RPE-derived macro-
phages, migrating into outer retinal layers owing to reactive
metabolic activity induced by the neovascular process.
These depolarizing foci were typically found at the ONL
level and corresponded tightly to accumulations of hyper-
reflective material in intensity-based SD OCT. This indi-
cates that depolarizing foci in outer retinal layers contain
melanin. Histopathological studies would be useful to
clarify the precise composition of depolarizing foci. The
decreasing amounts of ectopic depolarizing material in
outer retinal layers found in our study may also indicate a
dynamic response of the RPE following anti-VEGF therapy
supported by earlier findings of intraretinal RPE migration
in AMD using SD OCT, published by Ho and associates.36
The authors described the appearance of intraretinal RPE
migration in conventional SD OCT images in 61% of pa-
tients with early to intermediate dry AMD. Christenbury
and associates37 previously showed a positive correlation
between hyperreflective foci in SD OCT at baseline andJUNE 2015OPHTHALMOLOGY
TABLE. Interobserver Agreement Regarding Retinal Pigment Epithelium–Related Changes Identified by Polarization-Sensitive Optical
Coherence Tomography During Follow-up in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration
(Total: 31 Eyes)
Baseline Month 1 Month 3 Month 6 Month 12 Month 24 Mean
GA area (automatically detected) r 0.9 0.9 0.9 1.0 0.9 0.9
Percentage of Eyes Affected, by Respective Lesion Type
Focal RPE atrophy Grader 1 54.8 80.7 90.3 93.6 96.8 96.8
Grader 2 51.6 83.9 93.6 96.8 96.8 96.8
Difference% 5.9 3.8 3.5 3.3 0.0 0.0 2.8
k 0.81 0.80 0.88 0.79 1.00 1.00 0.88
95% CI 0.60–0.91 0.59–0.90 0.75–0.94 0.57–0.90 1.00–1.00 1.00–1.00
GA (presence per visit and patient) Grader 1 0.0 19.4 29.0 32.3 54.8 61.3
Grader 2 0.0 19.4 29.0 32.3 54.8 61.3
Difference% 0.0 0.0 0.0 0.0 0.0 0.0 0.0
k 1.00 1.00 1.00 1.00 1.00 1.00
95% CI 1.00–1.00 1.00–1.00 1.00–1.00 1.00–1.00 1.00–1.00
RPE porosity Grader 1 22.6 48.4 51.6 61.3 64.5 64.5
Grader 2 29.0 48.4 54.8 67.7 71.0 54.8
Difference% 22.2 0.0 5.9 9.5 9.1 15.0 10.3
k 0.91 0.85 0.89 0.93 0.93 0.81 0.89
95% CI 0.82–0.95 0.69–0.92 0.78–0.95 0.85–0.97 0.85–0.96 0.61–0.91
Accumulations of depolarizing
material at the RPE level
Grader 1 22.6 54.8 61.3 53.3 35.5 25.8
Grader 2 29.0 58.1 61.3 54.8 41.9 32.3
Difference% 22.2 5.5 0.0 2.8 15.3 20.2 11.00
k 0.91 0.89 0.93 0.97 0.85 0.91 0.91
95% CI 0.82–0.96 0.78–0.95 0.85–0.97 0.93–0.98 0.69–0.93 0.83–0.96
RPE thinning Grader 1 3.2 6.5 6.5 9.7 12.9 9.7
Grader 2 6.5 0.0 9.7 6.5 16.1 9.7
Difference% 49.9 100.0 33.4 33.4 20.0 0.0 39.5
k 0.79 0 0.26 0.88 0.52 0.42 0.39
95% CI 0.57–0.90 1.07 to 0.52 1.62 to 0.39 0.76–0.94 0.01–0.77 0.21 to 0.72
Ectopic depolarizing material in
outer retinal layers
Grader 1 83.9 87.1 80.7 74.2 61.3 51.6
Grader 2 83.9 90.3 80.7 71.0 38.7 35.5
Difference% 0.0 3.6 0.0 4.3 36.8 31.3 12.7
k 1.00 0.92 1.00 0.96 0.77 0.80 0.91
95% CI 1.00–1.00 0.82–0.95 1.00–1.00 0.92–0.98 0.53–0.89 0.59–0.91
CI ¼ confidence interval; GA ¼ geographic atrophy; k ¼ intraclass correlation coefficient; RPE ¼ retinal pigment epithelium.
The Spearman correlation coefficient of semiautomatically quantifiedGA lesions between both observerswas r¼ 0.9. Overall agreement was
88%between both graders regarding the assessment of RPE-specific lesions detected in polarization-sensitive optical coherence tomography
B-scans.GA development at 2 years of follow-up in intermediate
dry AMD. Further studies are needed to determine if depo-
larizing intraretinal foci are a predictive factor for progres-
sion of GA in neovascular AMD.
Fellow eye analysis in our study substantiates an associa-
tion between short-term progression of RPE changes and
therapy, as RPE-related findings described for eyes with
CNV were not found in fellow eyes without neovascular
AMD.
Regarding BCVA change under therapy, the loss ofz1
letter at month 24 compared to baseline may be related to
the relatively low number of patients included.VOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENICA limitation of this study is that the comparison of RPE
alterations found in polarization-sensitive OCT B-scans at
different visits lacked the implementation of an eye-
tracking system that would provide even more accurate
results. Fully automated determination of dimensions of
all RPE atrophies in a polarization-sensitive OCT dataset
will be developed in the future. However, this would require
a higher sampling density of polarization-sensitive OCT
B-scans and some improvements of the presently used GA
segmentation algorithm. Besides large GA lesions, focal
RPE atrophy lesions in patients with neovascular AMD
are mostly small and diffusely distributed. Furthermore,1111THERAPY IN NEOVASCULAR AMD
the semiautomated algorithm for GA detection has limita-
tions in delineating the atrophic zone in cases of severe
retinal edema. Nevertheless, ongoing development of soft-
ware algorithms may soon lead to further studies showing
the viability of automatic RPE lesion size detection in
neovascular AMD.
Moreover, although previous histologic studies33,34
support our hypothesis of increased metabolic activity,
migration, or cellular proliferation by adjacent RPE, a
direct histopathologic validation cannot be provided in
the setting of a clinical study. Experimental studies would
be necessary to provide histopathologic correlation
analyses.
Although polarization-sensitive OCT does not resolve
details within the RPE (ie, at a cellular level), the device
images structures like the outer hyperreflective band
described earlier38–40 based on the concurrent intensity
scans, which are part of the SD-based system. This layer
may represent the interdigitation of the apical processes
of the RPE with cone outer segments, termed ‘‘interdigi-
tation zone.’’38 When assessing polarization-sensitive
OCT intensity/RPE overlay images, the segmented
RPE frequently masks the outer hyperreflective band
because the segmented RPE layer thickness appears
wider than one would expect for healthy RPE, consisting
of a cell monolayer of a few micrometers in thickness.
The reason is a convolution of the real tissue extension1112 AMERICAN JOURNAL OFwith the evaluation window function for RPE detec-
tion.18 Thickness measurements may be improved by
deconvolution, requiring deeper knowledge about statis-
tics of the polarization state distribution caused by the
RPE. Furthermore, resolution in DOPU images is lower
than in intensity-based images generated by the
polarization-sensitive OCT device. Improvements may
be achieved by advancing depth resolution by a larger
source bandwidth41 or by 3-dimensional windowing,
requiring a larger sampling density in the y-direction.
This would provide an increased number of data points
for histogram calculations and/or smaller in-plane
window sizes, resulting in better resolution42 of the
segmented RPE.
In summary, this study revealed essential insights into
the morphologic response of the RPE in patients with
neovascular AMD treated with anti-VEGF over a
follow-up period of 24 months. Based on a novel
polarization-sensitive OCT technology, pathognomonic
changes could be identified qualitatively and monitored
quantitatively. Data strengthen the hypothesis of an
increased risk of GA with more intensive VEGF inhibi-
tion (ie, monthly retreatment). This knowledge may be
useful in routine clinical management, development of
future therapeutic strategies, and an improved moni-
toring of disease and therapy using advanced OCT tech-
nologies.ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTER-
est. No conflicting relationship exists for any author. C.K. Hitzenberger has received support by an independent scientific grant (FWF grant P19624-
B02, Austrian Science Fund, Vienna, Austria), the European Union (FP7 HEALTH program grant 201880, FUN-OCT, Brussels, Belgium), and Canon
(Tokyo, Japan). U. Schmidt-Erfurth receives consultancy and lecture fees and travel support from Alcon Laboratories, Inc (Fort Worth, Texas), Bayer
Healthcare (Vienna, Austria), Novartis (Basel, Switzerland), Allergan (Irvine, California), and Boehringer (Ingelheim, Germany). M. Pircher and B.
Baumann have received support from Canon (Tokyo, Japan). Polarization-sensitive OCT was constructed and provided by the Center for Biomedical
Engineering and Physics, Medical University of Vienna, Vienna, Austria. All authors attest that they meet the current ICMJE requirements to qualify as
authors.REFERENCES
1. Bressler NM, Bressler SB, Fine SL. Age-related macular
degeneration. Surv Ophthalmol 1988;32(6):375–413.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related
maculopathy. The Beaver Dam Eye Study. Ophthalmology
1992;99(6):933–943.
3. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of
age-related macular degeneration in the United States. Arch
Ophthalmol 2004;122(4):564–572.
4. Marmor MF. Retinal pigment epithelium in Ophthalmology.
St. Louis: Mosby;2004:775–778.
5. Jager RD, Mieler WF, Miller JW. Age-related macu-
lar degeneration. N Engl J Med 2008;358(24):
2606–2617.
6. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to
treat cancer and age-related macular degeneration. Annu Rev
Med 2007;58:491–504.7. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW,
Hartnett ME. Vascular endothelial growth factor in eye
disease. Prog Retin Eye Res 2008;27(4):331–371.
8. Grisanti S, Tatar O. The role of vascular endothelial growth
factor and other endogenous interplayers in age-related mac-
ular degeneration. Prog Retin Eye Res 2008;27(4):372–390.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP,
Ianchulev T, ANCHOR Study Group. Ranibizumab versus
verteporfin photodynamic therapy for neovascular
age-related macular degeneration: two-year results of the
ANCHOR study. Ophthalmology 2009;116(1):57–65.
10. CATT Research Group, Martin DF, Maguire MG, Ying GS,
Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab
for neovascular age-related macular degeneration. CATT
Research Group. N Engl J Med 2011;364(20):1897–1908.
11. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study
Group. Twelve-month efficacy and safety of 0.5 mg or
2.0 mg ranibizumab in patients with subfoveal neovascularJUNE 2015OPHTHALMOLOGY
age-related macular degeneration. Ophthalmology 2013;
120(5):1046–1056.
12. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J,
Klesert TR. MARINA Study Group. Improved vision-
related function after ranibizumab treatment of neovascular
age-related macular degeneration: results of a randomized
clinical trial. Arch Ophthalmol 2007;125(11):1460–1469.
13. Schmidt-Erfurth U, Eldem B, Guymer R, et al. EXCITE
Study Group. Efficacy and Safety of Monthly versus Quarterly
Ranibizumab Treatment inNeovascular Age-relatedMacular
Degeneration: The EXCITE Study. Ophthalmology 2011;
118(5):831–839.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med
2006;355(14):1419–1431.
15. Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK,
Spaide RF. Retinal pigment epithelial cell loss assessed
by fundus autofluorescence imaging in neovascular age-
related macular degeneration. Ophthalmology 2013;120(2):
334–341.
16. Grunwald JE, Daniel E, Huang J, et al. CATT Research
Group. Risk of Geographic Atrophy in the Comparison of
Age-related Macular Degeneration Treatments Trials.
Ophthalmology 2014;121(1):150–161.
17. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical
coherence tomography-guided, variable dosing regimen
with intravitreal ranibizumab (Lucentis) for neovascular
age-related macular degeneration. Am J Ophthalmol 2007;
143(4):566–583.
18. Go¨tzinger E, Pircher M, Geitzenauer W, et al. Retinal
pigment epithelium segmentation by polarization sensitive
optical coherence tomography. Opt Express 2008;16(21):
16410–16422.
19. Yamanari M, Makita S, Yasuno Y. Polarization-sensitive
swept-source optical coherence tomography with continuous
source polarization modulation. Opt Express 2008;16(8):
5892–5906.
20. Pircher M, Hitzenberger CK, Schmidt-Erfurth U.
Polarization sensitive optical coherence tomography in the
human eye. Prog Retin Eye Res 2011;30(6):431–451.
21. Schlanitz FG, Baumann B, Spalek T, et al. Performance of
automated drusen detection by polarization-sensitive optical
coherence tomography. Invest Ophthalmol Vis Sci 2011;52(7):
4571–4579.
22. Baumann B, Go¨tzinger E, Pircher M, et al. Segmentation and
quantification of retinal lesions in age-related macular
degeneration using polarization-sensitive optical coherence
tomography. J Biomed Opt 2010;15(6):061704.
23. Schu¨tze C, Bolz M, Sayegh R, et al. Lesion size detection in
geographic atrophy by polarization sensitive optical coher-
ence tomography and correlation to conventional imaging
techniques. Invest Ophthalmol Vis Sci 2013;54(1):739–745.
24. Ahlers C, Go¨tzinger E, PircherM, et al. Imaging of the retinal
pigment epithelium in age-related macular degeneration
using polarization-sensitive optical coherence tomography.
Invest Ophthalmol Vis Sci 2010;51(4):2149–2157.
25. Schmitz-Valckenberg S, Fleckenstein M, Go¨bel AP,
Hohman TC, Holz FG. Optical coherence tomography and
autofluorescence findings in areas with geographic atrophy
due to age-related macular degeneration. Invest Ophthalmol
Vis Sci 2011;52(1):1–6.VOL. 159, NO. 6 RPE RESPONSE TO ANTIANGIOGENIC26. Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a
histopathological assessment. JAMA Ophthalmol 2014;
132(3):338–345.
27. Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T,
Wang J. Incidence and progression of geographic atrophy:
observations from a population-based cohort. Ophthalmology
2013;120(10):2042–2050.
28. Xu L, Blonska AM, Pumariega NM, et al. Reticular macular
disease is associated with multilobular geographic atrophy
in age-related macular degeneration. Retina 2013;33(9):
1850–1862.
29. Jaffe GJ, Martin DF, Toth CA, et al. Comparison of
Age-related Macular Degeneration Treatment Trials
Research Group. Macular morphology and visual acuity in
the comparison of age-related macular degeneration
treatment trials. Ophthalmology 2013;120(9):1860–1870.
30. Schmitz-Valckenberg S, Alten F, Steinberg JS, et al.
Reticular drusen associated with geographic atrophy in
age-related macular degeneration. Invest Ophthalmol Vis Sci
2011;52(9):5009–5015.
31. Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D,
Hiscott P. Histological findings of a choroidal neovascular
membrane removed at the time of macular translocation in
a patient previously treated with intravitreal bevacizumab
treatment (Avastin). Br J Ophthalmol 2007;91(5):602–604.
32. Semoun O, Guigui B, Tick S, Coscas G, Soubrane G,
Souied EH. Infrared features of classic choroidal neovascular-
isation in exudative age-related macular degeneration.
Br J Ophthalmol 2009;93(2):182–185.
33. Tsuboi S, Pederson JE, Toris CB. Functional recovery of
retinal pigment epithelial damage in experimental retinal
detachment. Invest Ophthalmol Vis Sci 1987;28(11):
1788–1794.
34. Rabenlehner D, Stanzel BV, Krebs I, Binder S, Goll A.
Reduction of iatrogenic RPE lesions in AMD patients:
evidence for wound healing? Graefes Arch Clin Exp
Ophthalmol 2008;246(3):345–352.
35. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G,
Kriechbaum K, Scholda C, Diabetic Retinopathy Research
Group Vienna. Optical coherence tomographic hyperreflec-
tive foci: a morphologic sign of lipid extravasation in diabetic
macular edema. Ophthalmology 2009;116(5):914–920.
36. Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal
retinal pigment epithelium migration via high-speed
ultrahigh-resolution optical coherence tomography.
Ophthalmology 2011;118(4):687–693.
37. Christenbury JG, Folgar FA, O’Connell RV, Chiu SJ,
Farsiu S, Toth CA, Age-related Eye Disease Study 2
Ancillary Spectral Domain Optical Coherence Tomography
Study Group. Progression of intermediate age-related
macular degeneration with proliferation and inner retinal
migration of hyperreflective foci. Ophthalmology 2013;
120(5):1038–1045.
38. Staurenghi G, Sadda S, Chakravarthy U, Spaide RF.
Proposed lexicon for anatomic landmarks in normal poste-
rior segment spectral-domain optical coherence tomogra-
phy: the INOCT consensus. Ophthalmology 2014;121(8):
1572–1578.
39. Spaide RF, Curcio CA. Anatomical correlates to the bands
seen in the outer retina by optical coherence tomography:
literature review and model. Retina 2011;31(8):1609–1619.1113THERAPY IN NEOVASCULAR AMD
40. Zhang QX, Lu RW, Messinger JD, Curcio CA, Guarcello V,
Yao XC. In vivo optical coherence tomography of
light-driven melanosome translocation in retinal pigment
epithelium. Sci Rep 2013;3:2644.
41. Go¨tzinger E, Pircher M, Baumann B, et al. Speckle noise
reduction in high speed polarization sensitive spectral domain1114 AMERICAN JOURNAL OFoptical coherence tomography. Opt Express 2011;19(15):
14568–14585.
42. Sugita M, Pircher M, Zotter S, et al. Analysis of optimum
conditions of depolarization imaging by polarization-
sensitive optical coherence tomography in the human retina.
J Biomed Opt 2015;20(1):16011.JUNE 2015OPHTHALMOLOGY
Biosketch
Christopher Schu¨tze, MD, is a resident at the Medical University of Vienna. He is an ophthalmologist with a focus on
clinical research in retinal diseases, in particular age-related macular degeneration using state of the art optical
coherence tomography and polarization-sensitive optical coherence tomography imaging. Dr Schu¨tze actively
participated in many conventions and is an avid lecturer and teacher.VOL. 159, NO. 6 1114.e1RPE RESPONSE TO ANTIANGIOGENIC THERAPY IN NEOVASCULAR AMD
